amikacin

Amikacin is a semi-synthetic aminoglycoside antibiotic primarily used to treat severe infections caused by aerobic Gram-negative bacteria, including those resistant to other aminoglycosides. It is effective against pathogens such as Pseudomonas aeruginosa, Acinetobacter spp., Enterobacteriaceae (including Escherichia coli, Proteus spp., Klebsiella spp., Serratia spp.), and some Gram-positive bacteria like Staphylococcus and Nocardia. Amikacin acts by binding irreversibly to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and leading to the production of abnormal proteins that disrupt cell membrane integrity and cause bacterial cell death. It is often reserved for cases where resistance limits other treatment options or as part of combination therapy for serious infections such as sepsis, meningitis, pneumonia (especially hospital-acquired), intra-abdominal infections (e.g., peritonitis), bone/joint infections, complicated urinary tract infections, skin/soft tissue infections, non-tuberculous mycobacterial disease (including multidrug-resistant tuberculosis), and neutropenic fever in cancer patients[1][3][4][5]. Amikacin can be administered intravenously or intramuscularly; topical forms exist for ophthalmic use.

Brand names

Amikin

Other names

阿米卡星丁胺卡那霉素硫酸阿米卡星